Skip to main content
. 2024 Nov 5:1–16. Online ahead of print. doi: 10.6004/jadpro.2024.15.8.21

Table 3. Comparison of Common Adverse Events Associated With Therapeutic Options in Follicular Lymphoma .

Adverse event Immunotherapy CAR T-cell BsAb EZH2 inhibitor PI3Ki
Rituximab Obinutuzumab Lenalidomide Axi-cel Tisa-cel Mosunetuzumab Tazemetostat Copanlisib
Blood and lymphatic system disorders
Cytopenia x x x x x
Anemia x x x x
Lymphopenia x x
Leukopenia x x x x x
Neutropenia x x x x x x
Thrombocytopenia x x x x x
Febrile neutropenia x
Cardiac disorders
Arrhythmias x
Tachycardia x
Gastrointestinal disorders
Abdominal pain x
Nausea x x x x
Vomiting x
Diarrhea x x x x
Constipation x x
Oral ulceration/stomatitis
General disorders and administration site conditions
IRR x x
Pyrexia/fever x x x x
Chills x x
Asthenia x
Fatigue x x x x x x x
Immune system disorders
Cytokine release syndrome x x x
Infections and infestations
Infection x x x
Nasopharyngitis
URTI x x x
Metabolism and nutrition disorders
Anorexia
Decreased appetite x
Weight loss
Hyperglycemia x
Musculoskeletal and connective tissue disorders
Musculoskeletal pain x x x x
Nervous system disorders
Dizziness x
Encephalopathy x
Headache x x x
Peripheral neuropathy
Tremor x
Respiratory, thoracic, and mediastinal disorders
Cough x x x
Dyspnea
Hypoxia x
Skin and subcutaneous tissue disorders
Alopecia
Rash x x
Vascular disease
Hypertension x
Hypotension x

Note. axi-cel = axicabtagene ciloleucel; BsAb = bispecific antibody; CAR T-cell therapy = chimeric antigen receptor T-cell therapy; EZH2 = enhancer of zeste homolog 2; IRR = infusion-related reaction; PI3Ki = phosphoinositide 3 kinase inhibitor; tisa-cel = tisagenlecleucel; URTI = upper respiratory tract infection.

HHS Vulnerability Disclosure